Triple therapy for the management of COPD: A review

COPD: Journal of Chronic Obstructive Pulmonary Disease

Volumn 8, Issue 3, 2011, Pages 206-243

  Gaebel, Kathryn ^a,b   McIvor, R Andrew ^a,c   Xie, Feng ^a,b   Blackhouse, Gord ^a   Robertson, Diana ^a   Assasi, Nazila ^e   Hernandez, Paul ^d   Goeree, Ron ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b CENTRE FOR EVALUATION OF MEDICINES   (Canada)

^c Firestone Institute for Respiratory Health   (Canada)

^d DALHOUSIE UNIVERSITY   (Canada)

^e NONE

Author keywords

Chronic Obstructive Pulmonary Disease; Inhaled bronchodilators; Inhaled corticosteroids; Systematic review; Triple therapy

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE PLUS FORMOTEROL; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; FLUTICASONE PROPIONATE PLUS SALMETEROL;

BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CINAHL; COCHRANE LIBRARY; COUGHING; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; DYSPHONIA; DYSPNEA; EMBASE; HEART ARRHYTHMIA; HEART INFARCTION; HEART PALPITATION; HOSPITALIZATION; HUMAN; HYPERTENSION; LUNG FUNCTION; MEDICAL LITERATURE; MEDLINE; META ANALYSIS; MONOTHERAPY; MORTALITY; MOUTH PAIN; NEOPLASM; PAIN; PLEURITIC PAIN; PNEUMONIA; PRIORITY JOURNAL; QUALITY OF LIFE; RESPIRATORY FAILURE; REVIEW; RHINOPHARYNGITIS; RISK ASSESSMENT; SYSTEMATIC REVIEW; THRUSH; TREMOR; UPPER RESPIRATORY TRACT INFECTION; XEROSTOMIA;

ADRENAL CORTEX HORMONES; ADRENERGIC BETA-AGONISTS; BRONCHODILATOR AGENTS; CHOLINERGIC ANTAGONISTS; DRUG THERAPY, COMBINATION; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 79957594673     PISSN: 15412555     EISSN: 15412563     Source Type: Journal    
DOI: 10.3109/15412555.2011.560131     Document Type: Review

References (36)

1. Todd DC, McIvor RA, Pugsley SO, Cox G. Approach to chronic obstructive pulmonary disease in primary care. Can Fam Physician 2008 May; 54(5):706-711. (Pubitemid 351838493)
2. McIvor RA. Future options for disease intervention: Important advances in phosphodiesterase 4 inhibitors. Eur Respir Rev 2007; 16(105):105-112. (Pubitemid 350276869)
3. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 1997 May 24; 349(9064):1498-1504. (Pubitemid 27216360)
4. Buist AS, McBurnie MA, Vollmer WM, Gillespie S, Burney P, Mannino DM, Menezes AM, Sullivan SD, Lee TA, Weiss KB, Jensen RL, Marks GB, Gulsvik A, Nizankowska-Mogilnicka E, BOLD Collaborative Research Group. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet 2007; 370(9589):741-750. (Pubitemid 47321907)
5. Caballero A, Torres-Duque CA, Jaramillo C, Bolivar F, Sanabria F, Osorio P, Orduz C, Guevara DP, Maldonado D. Prevalence of COPD in five Colombian cities situated at low, medium, and high altitude (PREPOCOL study). Chest 2008;133(2):343-9. (Pubitemid 351272390)
6. Gunen H, Hacievliyagil SS, Yetkin O, Gulbas G, Mutlu LC, Pehlivan E. Prevalence of COPD: first epidemiological study of a large region in Turkey. Eur J Intern Med 2008; 19(7):499-504.
7. Methvin JN, Mannino DM, Casey BR. COPD prevalence in southeastern Kentucky: the burden of lung disease study. Chest 2009; 135 (1):102-107.
8. van Durme YM, Verhamme KM, Stijnen T, van Rooij FJ, Van Pottelberge GR, Hofman A, Joos GF, Stricker BH, Brusselle GG. Prevalence, incidence, and lifetime risk for the development of COPD in the elderly: the Rotterdam study. Chest 2009; 135(2):368-377.
9. Dales RE, Aaron SD, Vandemheen KL, Mehdizadeh A, Clinch J. The prevalence of airflowobstruction in rural primary care. Respir Med 2006; 100(4):754-759. (Pubitemid 43285765)
10. Hill K, Goldstein RS, Guyatt GH, Blouin M, Tan WC, Davis LL, Heels-Ansdell DM, Erak M, Bragaglia PJ, Tamari IE, Hodder R, Stanbrook MB. Prevalence and underdiagnosis of chronic obstructive pulmonary disease among patients at risk in primary care. CMAJ 2010 April 20; 182(7):673-678.
11. Buist AS, Vollmer WM, Sullivan SD, Weiss KB, Lee TA, Menezes AM, Crapo RO, Jensen RL, Burney PG. The Burden of Obstructive Lung Disease Initiative (BOLD): Rationale and design. COPD 2005 June; 2(2):277-283. (Pubitemid 40993302)
12. Decramer M, Nici L, Nardini S, Reardon J, Rochester CL, Sanguinetti CM, Troosters T. Targeting the COPD exacerbation. Respir Med 2008 June; 102 Suppl 1:S3-15. (Pubitemid 351877091)
13. Toy EL, Gallagher KF, Stanley EL, Swensen AR, Duh MS.The economic impact of exacerbations of chronic obstructive pulmonary disease and exacerbation definition: a review. COPD 2010 June; 7(3):214-228.
14. Oostenbrink JB, Rutten-Van Molken MPMH. Resource use and risk factors in high-cost exacerbations of COPD. Respir Med 2004; 98(9):883-891. (Pubitemid 39069339)
15. Mittmann N, Kuramoto L, Seung SJ, Haddon JM, Bradley- Kennedy C, Fitzgerald JM.Thecost of moderate and severe COPD exacerbations to the Canadian healthcare system. Respir Med 2008 March; 102(3):413-421.
16. O'Donnell DE, Aaron S, Bourbeau J, Hernandez P, Marciniuk D, Balter M, Ford G, Gervais A, Goldstein R, Hodder R, Maltais F, Road J, McKay V, Schenkel J, Ariel A, Day A, Lacasse Y, Levy R, Lien D, Miller J, Rocker G, Sinuff T, Stewart P, Voduc N, Abboud R, Ariel A, Becklake M, Borycki E, Brooks D, Bryan S, Calcutt L, Chapman K, Choudry N, Couet A, Coyle S, Craig A, Crawford I, Dean M, Grossman R, Haffner J, Heyland D, Hogg D, Holroyde M, Kaplan A, Kayser J, Lein D, Lowry J, McDonald L, MacFarlane A, McIvor A, Rea J, Reid D, Rouleau M, Samis L, Sin D, Vandemheen K, Wedzicha JA, Weiss K. State of the art compendium: Canadian Thoracic Society recommendations for the management of chronic obstructive pulmonary disease. Can Respir J 2004 July; 11 Suppl B:7-59B.
17. McIvor RA. Tiotropium and chronic obstructive pulmonary disease. BMJ 2010; 340:c833.
18. American Thoracic Society, European Thoracic Society. American Thoracic Society/European Respiratory Society statement: standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency. Am J Respir Crit Care Med 2003; 168(7):818-900.
19. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. Bethesda (MD): National Heart, Lung and Blood Institute; 2008.
20. O'Donnell DE, Aaron S, Bourbeau J, Hernandez P, Marciniuk DD, Balter M, Ford G, Gervais A, Goldstein R, Hodder R, Kaplan A, Keenan S, Lacasse Y,Maltais F, Road J, Rocker G, Sin D, Sinuff T, Voduc N. CanadianThoracic Society recommendations for management of chronic obstructive pulmonary disease - 2007 update. Can Respir J 2007; 14(Suppl B):5-32B. (Pubitemid 350090390)
21. Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A selfcomplete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire. Am Rev Respir Dis 1992 June; 145(6):1321-1327.
22. Quirk FH, Jones PW. Patients' perception of distress due to symptoms and effects of asthma on daily living and an investigation of possible influential factors.Clin Sci (Lond) 1990 July; 79(1):17-21. (Pubitemid 20211337)
23. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, GavaghanDJ, McQuay HJ.Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996 February;17(1):1-12. (Pubitemid 26120810)
24. Schulz KF, Grimes DA. Allocation concealment in randomised trials: defending against deciphering. Lancet 2002 February 16; 359(9306):614-618. (Pubitemid 34178448)
25. Fang LZ, Liang X, Zhang JQ, Liu L, Fu WP, Zhao ZH, Dai LM. Combination of inhaled salmeterol/fluticasone and tiotropium in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial [in Chinese]. Zhonghua Jie He He Hu Xi Za Zhi 2008; 31(11):811-814.
26. Cazzola M, Ando F, Santus P, Ruggeri P, Di Marco F, Sanduzzi A, D'Amato M. A pilot study to assess the effects of combining fluticasone propionate/salmeterol and tiotropium on the airflow obstruction of patients with severe-to-very severe COPD. Pulm PharmacolTher 2007; 20(5):556-61. (Pubitemid 47077647)
27. Welte T, Miravitlles M, Hernandez P, Eriksson G, Peterson S, Polanowski T, Kessler R. Efficacy and tolerability of budesonide/formoterol added to tiotropium in COPD patients. Am J Respir Crit Care Med 2009 August 13; 180:741-750.
28. Aaron SD, Vandemheen KL, Fergusson D, Maltais F, Bourbeau J, Goldstein R, Balter M, O'Donnell D, McIvor A, Sharma S, Bishop G, Anthony J, Cowie R, Field S, Hirsch A, Hernandez P, Rivington R, Road J, Hoffstein V, Hodder R, Marciniuk D, McCormack D, Fox G, Cox G, Prins HB, Ford G, Bleskie D, Doucette S, Mayers I, Chapman K, Zamel N, FitzGerald M. Tiotropium in combination with placebo, salmeterol, or fluticasone- salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 2007; 146(8):545-555. (Pubitemid 351650535)
29. Donaldson GC, Seemungal TA, Patel IS, Lloyd-Owen SJ, Wilkinson TM,Wedzicha JA. Longitudinal changes in the nature, severity and frequency of COPD exacerbations. Eur Respir J 2003 December; 22(6):931-936. (Pubitemid 37540644)
30. Andersson F, Borg S, Jansson S-A, Jonsson A-C, Ericsson A, Prutz C, Ronmark E, Lundback B.The costs of exacerbations in chronic obstructive pulmonary disease (COPD). Respir Med 2002; 96(9): 700-708.
31. Jones PW. Interpreting thresholds for a clinically significant change in health status in asthma and COPD. Eur Respir J 2002 March; 19(3):398-404. (Pubitemid 34256951)
32. Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, Decramer M. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008 October 9; 359(15):1543-1554.
33. Cazzola M, MacNee W, Martinez FJ, Rabe KF, Franciosi LG, Barnes PJ, Brusasco V, Burge PS, Calverley PM, Celli BR, Jones PW, Mahler DA, Make B, Miravitlles M, Page CP, Palange P, Parr D, Pistolesi M, Rennard SI, Rutten-van Molken MP, Stockley R, Sullivan SD, Wedzicha JA, Wouters EF. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J 2008 February; 31(2):416-469.
34. LaCroix AZ, Lipson S, Miles TP, White L. Prospective study of pneumonia hospitalizations and mortality of U.S. older people: the role of chronic conditions, health behaviors, and nutritional status. Public Health Rep 1989 July; 104(4):350-360. (Pubitemid 19207539)
35. Mannino DM, Davis KJ, Kiri VA. Chronic obstructive pulmonary disease and hospitalizations for pneumonia in a US cohort. Respir Med 2009 February; 103(2):224-229.
36. O'Meara ES,White M, Siscovick DS, LylesMF, Kuller LH. Hospitalization for pneumonia in the Cardiovascular Health Study: incidence, mortality, and influence on longer-term survival. J Am Geriatr Soc 2005 July; 53(7):1108-16. (Pubitemid 41632509)